Efficacy and Safety of Platelet-Rich Plasma Intratympanic Injection for Sensorineural Hearing Loss.

Quedah, Ahmed Elsaied Abd Elgalel; Elkholy, Tawfik Abdelaty; Helaly, Mohamed Ibrahim; Abou Elenein, Ahmed Yehia; Beshry, Samedh Mamdoh; Kadis, Rania Rady

doi:10.21608/arcmed.2025.329420.1057

	Efficacy and Safety of Platelet-Rich Plasma Intratympanic Injection for Sensorineural Hearing Loss.
ARCADEs of MEDICINE
Volume 3, Issue 1, April 2025, Page 1-21 PDF (1.22 MB)
Document Type: Original Research
DOI: 10.21608/arcmed.2025.329420.1057
View on SCiNiTO
Authors
Ahmed Elsaied Abd Elgalel Quedah ¹; Tawfik Abdelaty Elkholy²; Mohamed Ibrahim Helaly³; Ahmed Yehia Abou Elenein²; Samedh Mamdoh Beshry⁴; Rania Rady Kadis⁵
¹Department of Otorhinolaryngology, Armed Forces Medical Complex, Alexandria, Egypt.
²Department of Otorhinolaryngology, Armed Forces College of Medicine, Cairo, Egypt.
³Department of Otorhinolaryngology, Military Medical Academy, Cairo, Egypt.
⁴Department of Audiovestibular, Armed Forces Medical Complex, Alexandria, Egypt.
⁵Department of Clinical Pathology Armed Forces Medical Complex, Alexandria, Egypt.
Abstract
Background: Sensorineural hearing loss (SNHL) is a significant auditory impairment affecting millions globally. Conventional treatments often provide limited efficacy, prompting the exploration of innovative therapies such as platelet-rich plasma (PRP) intratympanic injection, which leverages the regenerative properties of growth factors contained in PRP. Objectives: This study aims to evaluate the efficacy of PRP intratympanic injection in improving auditory function in patients with SNHL and to assess the safety profile of this treatment modality. Material and Methods: A follow-up interventional study was conducted on 30 patients diagnosed with mild to severe degrees of sensorineural hearing loss (SNHL) within a timeframe of 3 months to 5 years. Participants received intratympanic injections of platelet-rich plasma (PRP), with audiometric assessments performed at baseline and at six-month intervals post-injection. The primary outcome measures included pure-tone audiometry (PTA) and speech audiometry scores. Safety was monitored through patient-reported adverse effects and clinical observations. Results: The study included 30 participants, with significant improvements observed in PTA and speech audiometry scores six months post-PRP injection. The most notable improvements were recorded at frequencies of 1000 Hz and 2000 Hz. Adverse effects were minimal and transient, primarily consisting of mild dizziness and temporary tinnitus, both resolving spontaneously. Conclusions: PRP intratympanic injection is a promising treatment for SNHL, demonstrating significant improvement in auditory function with a favorable safety profile. Further large-scale studies are recommended to confirm these findings and to establish standardized treatment protocols.
Keywords
Hearing loss; intratympanic injection; platelet-rich plasma; pure-tone audiometry; sensorineural hearing loss


Statistics Article View: 323 PDF Download: 237